Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials.

ABSTRACT:

Objective

To assess the influence of drug; dosing regimen; and traditional, nontraditional, and genetic risk factors on the incidence of choroidal neovascularization (CNV) in the fellow eye of patients treated for CNV with ranibizumab or bevacizumab.

Design

Cohort study of patients enrolled in a multicenter, randomized clinical trial.

Participants

Patients with no CNV in the fellow eye at the time of enrollment in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Methods

Eligibility criteria for the clinical trial required that study eyes have evidence on fluorescein angiography and optical coherence tomography of CNV secondary to age-related macular degeneration (AMD) and visual acuity between 20/25 and 20/320. Treatment for the stud

SUBMITTER: Maguire MG 

PROVIDER: S-EPMC3758381 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature